These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28993541)

  • 21. Psychiatrists' attitude towards and knowledge of clozapine treatment.
    Nielsen J; Dahm M; Lublin H; Taylor D
    J Psychopharmacol; 2010 Jul; 24(7):965-71. PubMed ID: 19164499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychiatrists' decision making between branded and generic drugs.
    Hamann J; Mendel R; Kissling W; Leucht S
    Eur Neuropsychopharmacol; 2013 Jul; 23(7):686-90. PubMed ID: 23021566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival analysis of the use of first and second generation antipsychotics among patients suffering schizophrenia: A nationwide population-based cohort study.
    Chen VC; Liao YT; Lai TJ; Lane HY; Shao WC; Dewey M; Lee CT; Lu ML
    Schizophr Res; 2015 Dec; 169(1-3):406-411. PubMed ID: 26481616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attitudes of Croatian psychiatrists towards long-acting injectable antipsychotics.
    Ciglar M; Bjedov S; Maleković H
    Psychiatr Danub; 2016 Sep; 28(3):273-277. PubMed ID: 27658836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of oral versus long-acting antipsychotics on social functioning: A psychiatrists' survey in India.
    Gundugurti PR; Nagpal R; Sheth A; Narang P; Gawande S; Singh V
    Asian J Psychiatr; 2017 Dec; 30():88-93. PubMed ID: 28843143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychiatrists' attitudes toward metabolic adverse events in patients with schizophrenia.
    Sugawara N; Yasui-Furukori N; Yamazaki M; Shimoda K; Mori T; Sugai T; Suzuki Y; Someya T
    PLoS One; 2014; 9(1):e86826. PubMed ID: 24466260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients' attitudes towards generic substitution of oral atypical antipsychotics: a questionnaire-based survey in a hypothetical pharmacy setting.
    Roman B
    CNS Drugs; 2009 Aug; 23(8):693-701. PubMed ID: 19594198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey.
    Keenan A; Lin D; Shepherd J; Bailey H; Benson C; Meakin S
    BMC Psychiatry; 2022 Mar; 22(1):187. PubMed ID: 35300629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring for the metabolic side effects of second-generation antipsychotic medications: Psychiatrists' views and practices.
    Abdulhaq B; Dardas LA; Sami O
    Perspect Psychiatr Care; 2021 Jul; 57(3):1237-1243. PubMed ID: 33156542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antipsychotic use in patients with schizophrenia treated in private psychiatry.
    Simon AE; Peter M; Hess L; Valterio C
    Swiss Med Wkly; 2005 Feb; 135(7-8):109-15. PubMed ID: 15832227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The European psychiatric association (EPA) - early career psychiatrists committee survey on trainees' and early-career psychiatrists' attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment.
    Schoretsanitis G; Correll CU; Agorastos A; Compaired Sanchez A; Erzin G; Grigoras RM; Grizelj Benussi M; Gondek TM; Guloksuz S; Højlund M; Jerotic S; Kilic O; Metaj E; Sidhu DS; Skandali N; Skuhareuski A; Tveito M; Wolthusen RPF; ; Chumakov E; de Filippis R
    World J Biol Psychiatry; 2024 Jul; 25(6):342-351. PubMed ID: 38905131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-acting second-generation and oral antipsychotics for substance use disorders and psychotic symptoms: Prescribing attitudes among Italian psychiatrists.
    Corbo M; Martinotti G; Aguglia A; Salvi V; Amerio A; Calò S; Fusar-Poli L; Serafini G; Signorelli M; Amore M; Mencacci C; Di Sciascio G; Biggio G; Aguglia E; Di Giannantonio M
    Perspect Psychiatr Care; 2021 Oct; 57(4):1700-1706. PubMed ID: 33616260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicians' attitudes toward the use of long-acting injectable antipsychotics.
    Samalin L; Charpeaud T; Blanc O; Heres S; Llorca PM
    J Nerv Ment Dis; 2013 Jul; 201(7):553-9. PubMed ID: 23817151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international survey.
    Kurokawa S; Kishimoto T; Su KP; Chang JP; Chang HC; Yu X; Rodrigues-Silva N; Nielsen J; Unadkat A; Castle D; Haddad PM; Rocha D; Gadelha A; Kaliora S; Petrides G; Agid O; Tazawa Y; Takamiya A; Horigome T; Kane JM
    Schizophr Res; 2019 Sep; 211():105-107. PubMed ID: 31371039
    [No Abstract]   [Full Text] [Related]  

  • 36. Psychiatrists' awareness of partial- and non-adherence to antipsychotic medication in schizophrenia: results from the Australian ADHES survey.
    Kulkarni J; Reeve-Parker K
    Australas Psychiatry; 2015 Jun; 23(3):258-64. PubMed ID: 25783668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How do psychiatrists choose among different antipsychotics?
    Hamann J; Kolbe G; Cohen R; Leucht S; Kissling W
    Eur J Clin Pharmacol; 2005 Dec; 61(11):851-4. PubMed ID: 16235042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-generation antipsychotic medications and risk of chronic kidney disease in schizophrenia: population-based nested case-control study.
    Wang HY; Huang CL; Feng IJ; Tsuang HC
    BMJ Open; 2018 May; 8(5):e019868. PubMed ID: 29794090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001-2009).
    Xiang YT; Kreyenbuhl J; Dickerson FB; Ungvari GS; Wang CY; Si TM; Lee EH; He YL; Chiu HF; Yang SY; Chong MY; Tan CH; Kua EH; Fujii S; Sim K; Yong MK; Trivedi JK; Chung EK; Udomratn P; Chee KY; Sartorius N; Shinfuku N
    Aust N Z J Psychiatry; 2012 Dec; 46(12):1159-64. PubMed ID: 22790175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.